Celgene reports positive data from Imnovid drug trial

Celgene has highlighted positive findings from a newly-published study of its EU-approved multiple myeloma therapy Imnovid (pomalidomide).

Data from the MM-003 phase III trial has been published in The Lancet Oncology, demonstrating the benefits of a combination therapy regimen including pomalidomide and low-dose dexamethasone.

Oral pomalidomide plus low-dose dexamethasone was shown to offer various advantages over high-dose dexamethasone among relapsed and refractory multiple myeloma patients who have failed at least two prior therapies with both bortezomib and lenalidomide.

Celgene's drug was able to provide benefits in terms of both progression-free and overall survival, thereby meeting its primary efficacy endpoint in the study.

This adds to the body of clinical evidence supporting pomalidomide, which is sold under the name Imnovid in the EU and Pomalyst in the US.

It was released in the UK last month and represents a new therapy option that can help to extend remissions among sufferers of this serious form of bone marrow cancer.